Flavoxate 200mg/5ml oral suspension

Objective: To verify analytical methods, suitability for its intended use is the goal of validation by Reverse Phase-High Performance Liquid Chromatography (RP-HPLC) method. Methods: A validated method for determining flavoxate hydrochloride was created using HPLC, which is a sensitive, exact, and straightforward technique. The inertsilC18 (150 mm×4.6 mm, 5µm) is used in this approach. The buffer, which included 3g of 1-hexane sulphonic acid, 3 ml of Orthophosphoric Acid (OPA) and 3 ml of Triethylamine (TMA), was combined with Acetonitrile (ACN) in a 650:350 ratio to form the mobile phase. At 293 nm, Ultraviolet (UV) detection was done. Results: The Retaining time for flavoxate HCl was found to be 2.43 min. It was discovered that the linearity range of flavoxate HCl was 800-1200 µg/ml, and that the regression equation was y=17118x+80943. R 2 = 0.981 was found to be the linearity regression coefficient value. It was discovered that the RSD for intra-and inter-day precision was less than 2 %. Flavoxate HCl was discovered to have Limit of Detection (LOD)-83.13734 and Limit of Quantitation (LOQ)-251.9313 values of µg/ml and µg/ml, respectively. After statistical analysis, the results are deemed satisfactory. Conclusion: This technique can be used to analyze bulk forms of the antimuscarinic medication flavoxate HCl with success.

Abstract licence: CC BY 4.0

The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway is a key therapeutic target for inflammatory and neoplastic diseases such as rheumatoid arthritis (RA) and certain types of cancer. Although several inhibitors have been approved for medical use, their associated adverse effects limit their therapeutic use. Therefore, it is essential to search for new, safer inhibitors. In this work, we applied computer-aided approaches consisting of consensus molecular docking and molecular dynamics using the JAK2 structure as a filter of 3330 drugs approved by the Food and Drug Administration (FDA) retrieved from the ZINC20 database. The best predicted virtual hits were evaluated in an ex vivo STAT1,3 phosphorylation functional model in human lymphocytes induced by IL-6 stimulation. The docking-based consensus-scoring strategy allowed the selection of pitavastatin (PIT), eltrombopag (ELT), flavoxate (FLA), and empagliflozin (EMP) as potential JAK2 inhibitors. Their stability was confirmed by running independent molecular dynamics simulations of 200 ns in triplicate, which showed comparable stability with baricitib (BAR) and showed that hydrogen bonding is involved in their binding with key amino acids of the ATP-binding site. In the ex vivo evaluations, pitavastatin (0.5004 μM), eltrombopag (0.2548 μM), flavoxate (0.1536 μM), and empagliflozin (0.2548 μM) affected the phosphorylation of downstream STAT1 and STAT3 signaling molecules, similarly to tofacitinib citrate (TOF) (1.2 nM ). These results encourage further in-depth preclinical experiments aimed at exploring the additional effects of the JAK2-STAT1/3 signaling pathway.

Abstract licence: CC BY-NC-ND